The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Perspective
Volume 349:1987-1990 November 20, 2003 Number 21
NextNext

Immunologic Targets in Psoriasis
Thomas S. Kupper, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Lebwohl, M.
-Related Article
 by Leonardi, C. L.
-PubMed Citation
In this issue of the Journal, two reports present data on the efficacy of two new biologic drugs for psoriasis. One of these drugs, etanercept, has been used extensively in rheumatology and targets the pleiotropic inflammatory cytokine tumor necrosis factor {alpha} (TNF-{alpha}). The other, efalizumab, targets CD11a, or {alpha}L, one chain of {alpha}L {beta}2 integrin, also known as leukocyte-function–associated antigen 1 (LFA-1); LFA-1 is important in the process by which T cells cross blood-vessel walls, enter tissue, and are subsequently activated by antigen. Increasingly, molecules that were once the exclusive domain of immunologic scientists have entered mainstream medicine.

Etanercept consists of the . . . [Full Text of this Article]


Source Information

From the Department of Dermatology, Brigham and Women's Hospital, Boston.


Related Letters:

Etanercept for Crohn's Disease
Travers S. B., Kupper T. S.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:840, Feb 19, 2004. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.